

1 **Positive and negative affect, related mental health traits, and cognitive**
2 **performance: shared genetic architecture and potential causality**

3 Chloe Slaney^{1,2}, Naoise Mac Giollabhui³, Peter J. van der Most⁴, Ensor R. Palacios¹, Harold
4 Snieder⁴, Michel Nivard¹, Gibran Hemani¹, Catharina A. Hartman^{5*}, Golam M. Khandaker^{1,2,6,7*}.

5

6 ¹ Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of
7 Bristol, UK.

8 ² Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
9 University of Bristol, UK.

10 ³ Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General
11 Hospital, USA.

12 ⁴ Department of Epidemiology, University of Groningen, University Medical Center Groningen,
13 the Netherlands.

14 ⁵ Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry,
15 University of Groningen, University Medical Center Groningen, the Netherlands.

16 ⁶ NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS
17 Foundation Trust and University of Bristol, UK.

18 ⁷ Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

19

20 *Joint Senior Author

21

22 **Corresponding author:** Dr Chloe Slaney, MRC Integrative Epidemiology Unit, University of
23 Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, Email: chloe.slaney@bristol.ac.uk.

24

25 **Word count:**

26 Abstract: 323

27 Manuscript: 5,691 (includes tables/figure titles/footnotes)

28

29 **Keywords:** Positive Affect; Negative Affect; Depression; Anxiety; Cognition; General Cognitive
30 Ability; Lifelines Cohort; GWAS; Genetic Correlation; Mendelian randomization.

31

32

33

34

35 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36

Abstract

37 Altered affect and cognitive dysfunction are transdiagnostic, burdensome, and
38 pervasive features of many psychiatric conditions which remain poorly understood and
39 have few efficacious treatments. Research on the genetic architecture of these
40 phenotypes and causal relationships between them may provide insight into their
41 aetiology and comorbidity. Using data from the Lifelines Cohort Study, we conducted
42 genome-wide association studies (GWAS) on positive and negative affect and four
43 cognitive domains (working memory, reaction time, visual learning and memory,
44 executive function). Using publicly available large GWAS on related - albeit distinct-
45 phenotypes (depression, anxiety, wellbeing, general cognitive ability [GCA]) we
46 conducted genetic correlation and Mendelian randomization (MR) analyses to examine
47 genetic overlap and causal relationships. We identified one genome-wide hit ($p < 5 \times 10^{-8}$)
48 for reaction time, and many loci with suggestive associations ($p < 5 \times 10^{-6}$; N range= 11-20
49 independent hits) for other phenotypes. For most phenotypes, gene mapping and
50 tissue expression analysis of suggestive hits from the GWAS showed increased gene
51 expression in brain tissue compared to other tissues. As predicted, negative affect is
52 genetically correlated with mental health phenotypes (depression $r_g = 0.51$; anxiety
53 $r_g = 0.70$; wellbeing $r_g = -0.71$) and cognitive domains are genetically correlated with GCA
54 and brain volume ($r_g \leq 0.66$). Genetic correlations between negative and positive affect
55 suggest that they are dissociable constructs ($r_g = -0.18$) with negative affect having
56 higher genetic overlap with GCA than positive affect ($r_g = -0.19$ vs -0.06). This could
57 indicate that negative affect has a higher shared neural basis with GCA than positive
58 affect and/or GCA and negative affect may exhibit causal relationships. MR analyses
59 suggest potential causal effects of higher GCA on reduced negative affect, reduced risk
60 of depression and anxiety, and higher wellbeing, but little impact on positive affect. We
61 also report evidence for potential causal effects of depression and lower wellbeing on
62 reduced GCA. Taken together, these results suggests that GCA may be a valid target for
63 negative affect (but not positive affect) and depression and wellbeing may be valid
64 targets for GCA.

65

66

67 1. Introduction

68 Positive and negative affect reflect the extent to which a person feels positive or
69 negative emotions (e.g., excited, interested; nervous, distressed), respectively. Positive
70 and negative affect can be experienced in a state (temporary) or trait (stable) manner
71 (Watson et al., 1988) and are distinct transdiagnostic features of many health
72 conditions, particularly depression and anxiety. Another critical yet often overlooked
73 transdiagnostic feature of many health conditions is cognitive dysfunction (Colwell et
74 al., 2022; Hilton et al., 2024). Despite altered affect and cognitive dysfunction being
75 burdensome and pervasive features of many conditions, they remain poorly understood
76 and have few efficacious treatments (Colwell et al., 2022; Rush et al., 2006).

77 Understanding the genetic architecture of mental health and cognitive
78 phenotypes, and their relation to each other, can provide aetiological and biological
79 insights which may facilitate identification of novel treatment targets (Carey et al., 2021;
80 Minikel et al., 2024). Although observational studies have found associations between
81 mental health and cognition (Dam et al., 2021; Rock et al., 2014; Zainal & Newman,
82 2021; although see Ball et al., 2024;), causality remains unclear (Suddell et al., 2023).
83 Reported associations may reflect: (1) poorer mental health causing poorer cognition,
84 (2) poorer cognition causing poorer mental health, (3) confounding via shared risk
85 factors (e.g., stress, sedentary behaviour) (Mac Giollabhui, 2021). Crucially, studies
86 testing causal relationships between more narrowly defined mental health phenotypes
87 (e.g., affect) and cognitive domains (e.g., memory, attention) are needed (Chavez-
88 Baldini et al., 2023). Evidence of bidirectional causality would strengthen the case that
89 targeting poor mental health (either diagnostic conditions or transdiagnostic
90 phenotypes) may prevent and treat cognitive dysfunction, and *vice versa*. Two
91 approaches that can shed light on the aetiology, comorbidity, and/or causal
92 relationships between phenotypes are genetic correlations (using all genome-wide
93 variants) (Bulik-Sullivan, Finucane, et al., 2015) and Mendelian randomization (MR)
94 (typically using genome-wide association study hits) (Davey Smith & Ebrahim, 2003).
95 MR can test for causality given certain assumptions are met (see Supplementary
96 Methods). It does this by using genetic variants robustly associated with the exposure
97 as a proxy for it. The properties of genetic variants (random assignment from parents,
98 fixed at conception) mean that they are less likely to be associated with confounders
99 and overcome issues of reverse causality (Davey Smith & Ebrahim, 2003; Sanderson et
100 al., 2022). These methods provide powerful tools given the availability of large genome-
101 wide association studies (GWAS) on well-defined phenotypes.

102 To date, GWAS on mental health phenotypes have largely been conducted on
103 diagnostic categories such as depression and anxiety (Carey et al., 2021). However,
104 these conditions are heterogeneous, with diagnosed individuals showing diverse
105 symptom profiles. For example, a diagnosis of depression requires $\geq 5/9$ diverse
106 symptoms to be present within a two-week period, one of which must be low mood or
107 anhedonia (Regier et al., 2013). In addition, symptoms are often not specific to a
108 condition, meaning that GWAS on a condition may in reality capture a broader

109 phenotype. One potential approach to reducing phenotypic heterogeneity while
110 addressing the overlap with other conditions, is to focus on *more narrowly defined* traits
111 that more closely map onto biological systems (positive and negative affect, specific
112 cognitive domains) (Wendt et al., 2020). In line with the Research Domain Criteria
113 framework (Cuthbert, 2014; Insel et al., 2010), these are often transdiagnostic. GWAS
114 on these more narrowly defined transdiagnostic traits may potentially facilitate insights
115 into aetiology, comorbidity, and novel therapeutics.

116 In this study, we first conducted GWAS of negative and positive affect (assessed
117 using the Positive and Negative Affect Schedule [PANAS]) and cognitive task
118 performance in several domains (executive function, working memory, visual learning
119 and memory, and reaction time). Second, we conducted gene mapping and tissue
120 expression analysis to gain greater insight into associated genetic variants. Third, we
121 investigated genetic overlap between mental health (negative affect, positive affect,
122 depression, anxiety, wellbeing) and cognitive (general cognitive ability [GCA], specific
123 cognitive domains) phenotypes using genetic correlations. Fourth, we tested evidence
124 of potential causality between mental health and cognitive phenotypes using MR
125 analyses. This is the first GWAS conducted on positive and negative affect using well-
126 validated measures of these phenotypes. To achieve this, we use a large Dutch
127 population-based cohort, the Lifelines Cohort. The application of MR to test evidence of
128 causal relationships between affect and cognition is critical for improving our
129 conceptual understanding of these phenotypes.

130 We hypothesised that: (i) follow-up analyses on all GWAS show increased gene
131 expression in brain tissue compared to other tissues; (ii) affect and cognitive measures
132 in the Lifelines Cohort genetically correlate with related (albeit distinct) phenotypes
133 from external GWAS. Specifically, negative affect positively correlates with
134 depression/anxiety and negatively correlates with wellbeing (reverse direction for
135 positive affect), and higher cognitive performance on all domains correlates with GCA;
136 (iii) there are bidirectional causal relationships between mental health and cognitive
137 phenotypes.

138

139

140

141

142


143

144

145

146

147 **Figure 1. Study Objectives.**



148

149 **2. Methods and Materials**

150

151 **2.1. Description of the Lifelines Cohort**

152 Lifelines is a multi-disciplinary prospective population-based cohort study
 153 examining in a unique three-generation design the health and health-related behaviours
 154 of 167,729 persons living in the north of the Netherlands. It employs a broad range of
 155 investigative procedures in assessing the biomedical, socio-demographic, behavioural,
 156 physical and psychological factors which contribute to the health and disease of the
 157 general population, with a special focus on multi-morbidity and complex genetics.
 158 Participants were recruited between 2006-2013 via their GP (49%), participating family
 159 members (38%), and self-registration on the Lifelines website (13%) (Scholtens et al.,
 160 2015). Exclusion criteria for GP recruitment were: insufficient knowledge of Dutch
 161 language, severe psychiatric or physical illness, limited life expectancy (<5 years)
 162 (Scholtens et al., 2015). Baseline data included approximately: 15,000 children (0-17
 163 years), 140,000 adults (18-65 years), 12,000 elderly individuals (65+ years). Following
 164 baseline, participants completed follow-up questionnaires every 1.5 years and study
 165 visits every 5 years (1st follow-up visit [2014-2017], 2nd follow-up visit [2019-2023])
 166 (Scholtens et al., 2015; Sijtsma et al., 2022). In this study, we included participants ≥18
 167 years who were genotyped on a GWAS array and excluded participants who have
 168 conditions with a significant cognitive sequel: Alzheimer's disease, other dementia,

169 epilepsy, multiple sclerosis, Parkinson's disease, and stroke.

170

171 2.2. *Assessment of Positive and Negative Affect*

172 The Positive and Negative Affect Scale (PANAS) was used. PANAS assesses
173 positive and negative affect using two separate sub-scales, each containing 10 items
174 (example items: excited, upset, nervous) (Crawford & Henry, 2004; Watson et al., 1988).
175 Participants rate the extent they experienced each item during the last four weeks on a
176 five-point scale (ranging from 'not at all' to 'extremely'). The outcome is the summed
177 score on each subscale, which ranges from 10-50 (higher values reflect higher positive
178 or negative affect). The scales have high internal consistency ($\alpha=.87$) and moderate test-
179 retest reliability over 8-weeks (positive $r=.58$; negative $r=.48$) (Watson et al., 1988).

180

181 2.3. *Assessment of Cognitive Performance*

182 Ruff Figural Fluency Test (RFFT) was used, which is a valid and reliable measure
183 of executive functioning (Ross, 2014). The task consists of five parts, each containing 35
184 identical five-dot patterns. Participants draw as many unique designs as possible within
185 one minute by connecting dots in different patterns (Kuiper et al., 2017). The primary
186 outcome is total number of unique designs.

187 Four tasks from the CogState Test Battery were administered in Lifelines, which
188 tap into specific cognitive domains: visual learning & memory (one card learning task),
189 reaction time/attention (identification task and detection task) and working memory
190 (one-back task). As the detection and identification task both assess reaction time, we
191 include only the identification task in this study which has a larger sample size. We used
192 the recommended primary outcomes for all tasks. All outcomes were transformed
193 (reaction time [ms] on the identification task was log10 transformed, and accuracy on
194 the one-back and one card learning task were arcsine transformed). On both memory
195 tasks, higher values reflect better memory; on the reaction time task higher values
196 reflect poorer performance (i.e., slower reaction time). See Supplementary Methods for
197 further information on dataset preparation.

198

199 2.4. *Genetics Data and Quality Control*

200 Genotyping was conducted using three chip arrays in three subsets of the
201 Lifelines cohort: (i) Illumina CytoSNP-12 Bead Chip v2 array (N=17,033), (ii) Infinium
202 Global Screening Array (GSA) Beadchip-24 v1.0 (N=38,030), (iii) FinnGen Thermo Fisher
203 Axiom® custom array (Affymetrix; N=29,166). See Supplementary for quality control
204 (QC) and imputation procedures conducted by Lifelines. Following Lifelines QCs,
205 73,086 participants were potentially eligible for this study (CytoSNP N=14,942; GSA
206 N=31,810; Affymetrix N=26,334). We applied additional QCs, removing: (i) duplicates
207 (individuals genotyped on >1 chip) and 1st-degree relatives between chips, (ii) non-
208 European individuals, and (iii) genetic outliers, see Supplementary Figure S1. Following

209 additional QCs, 58,713 participants with genetics data were included in this study
210 (CytoSNP N=7,632; GSA N=24,975; Affymetrix N=26,106).
211

212 2.5. *GWAS Summary Statistics for Related Mental Health and Cognitive Phenotypes*

213 To examine genetic overlap and potential causality between affect and cognitive
214 performance, we used summary statistics from large publicly available GWAS of
215 depression (N Cases=294,322; N Controls=741,438) (Als et al., 2023), anxiety (N
216 Cases=7,016; N Controls=14,745)(Otowa et al., 2016), wellbeing (N=2,370,390)
217 (Baselmans et al., 2019), general cognitive ability (GCA; N=373,617)(Lam et al., 2021),
218 and brain volume (N=47,316) (Jansen et al., 2020). See Supplementary Methods and
219 Table S1-S2 for further details on these GWAS.
220

221 2.6. *Statistical Analyses*

222 2.6.1. *GWAS of Negative Affect, Positive Affect, and Cognitive Performance in Lifelines*

223 We conducted GWAS (negative affect score, positive affect score, and cognitive
224 performance score on each task) in each genotyped subset separately using REGENIE,
225 which accounts for relatedness (Mbatchou et al., 2021). Prior to conducting GWAS,
226 within each subset, we standardised all outcomes (mean=0; SD=1) and used PLINK
227 (Purcell et al., 2007) to clean the genetics data for REGENIE Step 1. We included
228 variants that met the following criteria: call rate (0.95), Hardy-Weinberg equilibrium (1e-
229 6), minor allele count (100), minor allele frequency (0.01), not multi-allelic; and
230 restricted to individuals with low missingness (0.95). In each GWAS, covariates included
231 age, sex, and top 10 genetic principal components. We excluded poorly imputed
232 variants (INFO score <0.8). For each outcome, we meta-analysed GWAS across the
233 three subsets using STDERR model in METAL and applied genomic corrections (Willer et
234 al., 2010). GWAS quality was inspected using GWAS Inspector 1.6.4.0 (Ani et al., 2021).
235 The standard p-value threshold of 5×10^{-8} was used to determine genome-wide
236 significance (for suggestive significance: p-value $< 5 \times 10^{-6}$). Variants with MAF < 0.01 were
237 excluded from all follow-up analyses.

238 2.6.2. *Tissue Specificity of Prioritised Genes*

239 We used gene and tissue mapping to explore associated variants in each GWAS.
240 We used an online platform (FUMA) which integrates resources to annotate, prioritize,
241 and visualise the summary statistics (Watanabe et al., 2017). The SNP2GENE function
242 was used to annotate SNPs and prioritise genes at each locus using positional
243 mapping. Using these prioritised genes, we used GENE2FUNC to investigate tissue
244 specificity of differentially expressed gene (DEG) sets using GTEx v8 data on 54 non-
245 diseased tissue types (N≤838 adults). For further details, see Supplementary Methods.

246 2.6.3. *Genetic Correlations*

247 Linkage Disequilibrium Score Regression (LDSR) (Bulik-Sullivan et al., 2015;
248 Bulik-Sullivan et al., 2015) was used to estimate genetic correlations of mental health

249 and cognitive phenotypes. This included phenotypes from Lifelines (positive and
250 negative affect, cognitive performance), and phenotypes from large external GWAS
251 (depression, anxiety, wellbeing, GCA, brain volume). We used precomputed LD scores
252 calculated using 1000G European data. As low imputation quality may confound LDSR
253 we filtered to HapMap3 panel SNPs which tend to be well-imputed in most studies
254 (Bulik-Sullivan, Finucane, et al., 2015). If GWAS did not have a sample size column for
255 SNPs, we assumed the same sample size for all SNPs. We checked all phenotypes had
256 heritability z-scores > 4 in line with standard procedure (Bulik-Sullivan et al., 2015). For
257 LDSR cleaning filters applied, see (Bulik-Sullivan et al., 2015).
258

259 2.7. Bidirectional Mendelian Randomization

260 MR was performed to investigate potential causal effect of mental health
261 phenotypes on cognition and *vice versa*. This was done in R v4.2.2 using *TwoSampleMR*
262 (Hemani et al., 2017) and *CAUSE* v1.2.0.0335 (Morrison et al., 2020).

263 We applied the following criteria to identify genetic instruments: (1) $p < 5 \times 10^{-8}$ (if
264 not available, a lenient $p < 5 \times 10^{-6}$ threshold was used) (2) independent ($r^2 < 0.01$, kb =
265 1000; based on European clustering in the 1000 genomes reference panel using
266 *ld_clump()* in the *ieugwasr* package (Hemani et al., 2024)), (3) minor allele frequency
267 (MAF) $\geq 1\%$. Any SNPs not available in the outcome GWAS were excluded. For primary
268 analyses, we used the Inverse-Variance Weighted method (> 1 SNP available) or Wald
269 ratio (if only 1 SNP was available). Where multiple genetic variants were available, we
270 conducted sensitivity analyses using different MR methods which have different
271 assumptions regarding the validity of the genetic instruments: MR-Egger (Bowden et al.,
272 2015), weighted median (Bowden et al., 2016), weighted mode (Hartwig et al., 2017).

273 We also applied Steiger filtering to assess whether genetic variants have stronger
274 associations with exposures than outcomes (Hemani et al., 2017). Given the possibility
275 of correlated pleiotropy, we additionally applied causal analysis using summary effect
276 estimates (CAUSE) which accounts for correlated and uncorrelated pleiotropy
277 (Morrison et al., 2020). For CAUSE, we included genome-wide variants pruned using
278 default criteria ($r^2 = 0.01$, p -value = 0.003) based on European 1000 genomes reference
279 panel. Given the possibility of population-level confounding (e.g., dynastic effects), we
280 also conducted within-sibship MR in the MR-base platform (Hemani et al., 2018) using
281 publicly available within-sibship GWAS on wellbeing, depressive symptoms, and
282 cognitive ability (Howe et al., 2022); see Supplementary methods for more detail. We
283 also checked for heterogeneity (Cochran's Q-statistic) and pleiotropy (Egger intercept).
284 For further details on assumptions of different MR methods used here, see
285 Supplementary methods.

286 In our primary analysis, we included phenotypes which have well-powered
287 GWAS as exposures (> 1 SNP available: depression, wellbeing, GCA). In secondary
288 analysis, we included phenotypes which have less well-powered GWAS as exposures (1

289 SNP or lenient p-value criteria: anxiety, negative affect, positive affect) to investigate
290 whether similar patterns of effects are observed for these phenotypes.

291 3. Results

292

293 3.1. GWAS of Negative Affect, Positive Affect, and Cognitive Performance in the 294 Lifelines Cohort

295 No SNPs met genome-wide significance threshold ($p < 5 \times 10^{-8}$), except one SNP for
296 reaction time (rs2920287, MAF=0.04, $p = 1.907 \times 10^{-8}$). Visual inspection of the locus zoom
297 plot of the region around rs2920287 shows many nearby genes, with PSCA being in
298 closest proximity (Figure S4). Follow-up analyses of this SNP using the GWAS Catalog
299 did not show associations with any traits. Lowering the threshold to $p < 5 \times 10^{-6}$ yielded
300 associated SNPs for all phenotypes (Table 1). For Manhattan plots, see Figures S2-S3.

301 **Table 1.** GWAS Results of Positive Affect, Negative Affect, and Cognitive Performance in
302 the Lifelines cohort.

Phenotype	N	Hits ($p < 5 \times 10^{-8}$)	Hits Clumped (1000kb, $r^2 = 0.01$)	Hits ($p < 5 \times 10^{-6}$)	Hits Clumped (1000kb, $r^2 = 0.01$)
Positive affect	57,946	0	0	67	20
Negative affect	57,946	0	0	73	15
Executive function	36,563	0	0	108	12
Visual learning and memory	36,783	0	0	139	12
Reaction time	35,729	1	1	176	19
Working memory	36,349	0	0	56	11

303 Note: Variants with MAF < 0.01 excluded.

304

305 3.2. Tissue Specificity of Prioritised Genes

306 We used a lenient p-value threshold ($p < 5 \times 10^{-6}$) to identify SNPs for follow-up
307 analysis in FUMA. For all phenotype's, prioritised genes were upregulated across
308 multiple tissue types, particularly brain tissue (see Supplementary Figures S5-S6 and
309 Tables S18-S23). Following FUMAs default Bonferroni corrections for multiple
310 comparisons, there was significant upregulation in brain tissue for positive affect
311 (substantia nigra) and visual learning and memory (cerebellum and cerebellar
312 hemispheres) compared to other tissue types. For visualisation of tissue specificity of
313 prioritised genes, see Figures S5-S6.

314

315

316 **3.3. Genetic Correlations between Affect and Mental Health Phenotypes**

317 **3.3.1. Negative Affect is Genetically Correlated with Mental Health Phenotypes**

318 Negative affect score was genetically correlated with depression ($r_g = 0.51$
 319 [SE=0.05], $p=2.80E-28$), wellbeing ($r_g = -0.71$ [SE=0.05], $p=8.65E-41$), and anxiety ($r_g =$
 320 0.70 [SE=0.18], $p=0.0002$). Positive affect showed weaker genetic correlations with
 321 depression ($r_g = -0.11$ [SE=0.04], $p=0.005$), wellbeing ($r_g = 0.30$ [SE=0.05], $p=2.38E-09$),
 322 with little evidence for anxiety ($r_g = -0.16$ [SE=0.17], $p=0.33$).

323 **3.3.2. Cognitive Domains are Genetically Correlated with GCA**

324 Cognitive performance in Lifelines tasks were genetically correlated with the
 325 largest GWAS for GCA: executive function ($r_g=0.66$ [SE=0.07], $p=1.39E-23$), visual
 326 learning & memory ($r_g=0.54$ [SE=0.05], $p=6.90E-29$), working memory ($r_g=0.53$ [SE=0.06],
 327 $p=1.23E-18$), and reaction time ($r_g= -0.39$ [SE=0.06], $p=1.48E-12$).


328 **3.3.3. Compared to Positive Affect, Negative Affect has Stronger Genetic Correlation
 329 with GCA.**

330 There was a weak negative genetic correlation between positive and negative
 331 affect scores ($r_g = -0.18$ [SE=0.08], $p=0.016$). There was stronger evidence of genetic
 332 correlations between GCA and negative affect ($r_g = -0.19$ [SE=0.04], $p=7.56E-06$)
 333 compared to GCA and positive affect ($r_g = -0.06$ [SE=0.04], $p=0.18$).

334 For all results, see Figure 2 and Supplementary Table S3.

335

336 **Figure 2.** Genetic correlations between Lifelines phenotypes (negative affect, positive
 337 affect, cognitive performance) and external phenotypes (depression, anxiety, wellbeing,
 338 GCA, brain volume) using LDSR.



339
 340

GCA=General Cognitive Ability; EF=Executive Functioning; Memory=Visual Learning and Memory; Neg Affect=Negative Affect (PANAS); Pos Affect=Positive Affect (PANAS).

341

342 3.4. Potential Causal Effects: Results from Mendelian Randomization

343 3.4.1. Effect of Mental Health Phenotypes on Cognition

344 In primary analyses, across all MR methods there was consistent evidence for a
345 potential causal effect of depression on lower GCA (IVW estimate: -0.14 [95% CI= -0.19
346 to -0.09], $p=0.00000006$) and of one SD increase in wellbeing on higher GCA (IVW
347 estimate: 0.30 [95% CI= 0.13 to 0.46], $p=0.0004$) (Figure 3). These effects remained after
348 applying Steiger Filtering (Figure 4; Supplementary Tables S6-S9) and were supported by
349 MR CAUSE (Supplementary Table S24-S25). There was also evidence for a potential
350 causal effect of one SD increase in wellbeing on better executive functioning (IVW
351 estimate: 0.24 [95% CI= 0.03 to 0.44], $p=0.024$), and weak evidence of an effect on
352 memory (IVW estimate: 0.19 [95% CI= -0.02 to 0.41], $p=0.076$). However, these effects
353 were not consistent across MR methods and were not supported following Steiger
354 filtering (Figure 4; Supplementary Tables S6-S9).

355 In secondary analyses, there was evidence for a potential causal effect of one
356 SD increase in negative affect on poorer memory (IVW estimate: -0.15 [95% CI= -0.27 to
357 -0.03], $p=0.012$) and one SD increase in positive affect on better executive functioning
358 (IVW estimate: 0.16 [95% CI= 0.02 to 0.30], $p=0.024$). However, these effects were not
359 consistent across MR methods, see Figures 4 and Supplementary Tables S10-S13.

360 For other mental health and cognitive phenotypes, there was little evidence of
361 causality based on IVW estimates (Figures 4; Supplementary Tables S6-S14).
362 Confidence intervals (CIs) using within-sibship GWAS were very large with imprecise
363 estimates (Figure S16).

364 There was evidence of heterogeneity, with the strongest evidence in analyses of
365 depression and wellbeing on GCA, see Supplementary Table S15. There was little
366 evidence of horizontal pleiotropy (based on Egger Intercept; $ps \geq 0.14$), except for weak
367 evidence in MR analyses of depression on GCA ($p=0.084$) and executive function
368 ($p=0.048$); see Supplementary Table S16.

369

370 3.4.2. Effect of GCA on Mental Health Phenotypes

371 There was evidence for a potential causal effect of one SD increase in GCA on
372 lower negative affect (IVW estimate: -0.11 [95% CI= -0.16 to -0.05], $p=0.0002$), reduced
373 risk of depression (OR: 0.88 [95% CI=0.83 to 0.93], $p=0.00003$), and anxiety (OR: 0.64
374 [95% CI=0.51 to 0.81], $p=0.0002$), and higher wellbeing (IVW estimate: 0.02 [95% CI=
375 0.01 to 0.04], $p=0.011$) (Figure 3; Supplementary Table S4). However, effects were not
376 consistent across all MR methods: there was more consistent evidence for GCA on
377 negative affect (3/4 methods provide evidence supporting causality) compared to
378 depression (2/4), anxiety (2/4), and wellbeing (1/4).

379 Following Steiger Filtering, there was still evidence for a potential causal effect of
380 one SD increase in GCA on lower negative affect (IVW estimate: -0.07 [95% CI= -0.11 to
381 -0.02], $p=0.007$) but weaker evidence for one SD increase in GCA on reduced risk of

382 anxiety (IVW estimate: -0.24 [95% CI= -0.50 to 0.02], $p=0.072$), although CIs were large
383 (see Figure 4 and Supplementary Table S5). For GCA on depression and wellbeing,
384 results were unaltered as no variants were removed in Steiger Filtering. MR CAUSE
385 support that the data are consistent with a causal effect of GCA on negative affect,
386 depression, and wellbeing (See Supplementary Tables S24-S25). Although MR CAUSE
387 suggests the data for GCA on anxiety fit the causal model better than the null or sharing
388 model, this did not meet conventional p -value criteria ($p>0.05$). In within-sibship MR, CI
389 were very large with imprecise estimates (Figure S16).


390 There was strong evidence of heterogeneity in MR analyses testing effects of
391 GCA on mental health phenotypes, except for GCA on anxiety ($p=0.34$); see
392 Supplementary Table S15. There was little evidence of horizontal pleiotropy based on
393 MR Egger Intercept ($p_s \geq .15$) (Supplementary Table S16).

394

395

396

397 **Figure 3.** Mendelian Randomization Analyses Testing Evidence of Potential Causality
 398 between Mental Health and Cognition Phenotypes.




399
 400 *Note: Bars reflect 95% CIs. Axes differ to ensure inclusion of CIs for all analyses. For binary phenotypes (anxiety, depression), beta reflects log(OR).*

401

402

403 **Figure 4.** Steiger Filtered Mendelian Randomization Analyses Testing Evidence of
404 Potential Causality between Mental Health and Cognition Phenotypes.



405

406 *Note: Bars reflect 95% CIs. Axes differ to increase visibility of results in different analyses; CI of MR-Egger (cognition on anxiety) is absent on graph due to very*
407 *large CI. For binary phenotypes (anxiety, depression), beta reflects log(OR).*

408

409

410

411 4. Discussion

412 We conducted genome-wide association studies (GWAS) on negative and
413 positive affect using a well-validated scale (PANAS) and four cognitive domains
414 (executive function, working memory, visual learning and memory, reaction time) in the
415 Lifelines Cohort. We identified one genome-wide hit ($p < 5 \times 10^{-8}$) for reaction time, and
416 many loci with suggestive associations ($p < 5 \times 10^{-6}$) for other phenotypes. As predicted,
417 gene mapping and tissue expression analysis of suggestive hits show higher gene
418 expression in brain tissue compared to other tissues for most phenotypes; negative
419 affect is genetically correlated with mental health phenotypes (depression $r_g = 0.51$;
420 anxiety $r_g = 0.70$; wellbeing $r_g = -0.71$) and cognitive domains are genetically correlated
421 with GCA and brain volume ($r_g \leq 0.66$). Genetic correlations between negative and
422 positive affect suggest that they are dissociable constructs ($r_g = -0.18$); with negative
423 affect having higher genetic overlap with GCA than positive affect ($r_g = -0.19$ vs -0.06).
424 Importantly, MR results suggest evidence of potential causal effects of higher GCA on
425 reduced negative affect, reduced risk of depression and anxiety, and higher wellbeing
426 (with the most robust result being higher GCA on reduced negative affect), but little
427 impact of GCA on positive affect. We also report evidence for potential causal effects of
428 depression and lower wellbeing on reduced GCA. Taken together, these results suggests
429 that GCA may be a valid target for reducing negative affect, but not for increasing
430 positive affect; and depression and wellbeing may be valid targets for GCA.

431 4.1. Potential Causality between Mental Health and Cognitive Phenotypes

432 Across different MR methods, we found evidence of a potential causal effect of
433 higher GCA on many mental health outcomes (reduced negative affect, reduced risk of
434 depression and anxiety, increased wellbeing). There was also evidence of potential
435 causal effects of depression and wellbeing on GCA. Whilst we did not observe evidence
436 for negative affect and anxiety on GCA, given the consistent direction of effect, this may
437 be due to these GWAS being smaller and having decreased statistical power when used
438 as exposures. Our findings complement recent studies using MR analyses and
439 complementary designs (e.g., within-sibship analyses) reporting evidence of causality
440 between mental health phenotypes (depression, wellbeing, and/or anxiety) and
441 constructs related to cognition [e.g., educational attainment (Demange et al., 2024),
442 education duration (Van De Weijer et al., 2024)].

443 However, few studies have directly tested causality between mental health and
444 cognition. Using MR analyses in the ALSPAC cohort, Suddell et al. (2023) tested
445 causality between mental health conditions (depression, anxiety) and specific cognitive
446 domains (response inhibition, working memory, emotion recognition) but reported that
447 estimates were imprecise likely due to limited statistical power (Suddell et al., 2023).
448 Marchi et al. (2024) used multivariable MR to test the causal effect of GCA and poverty
449 on several mental health conditions (including depression and anxiety) (Marchi et al.,
450 2024). After adjusting for poverty, they found evidence that higher GCA may causally
451 reduce risk of depression and anxiety. Through inclusion of additional GWAS (negative
452 affect, positive affect, larger depression GWAS), our findings lend support to these

453 findings and additionally suggest: (1) higher GCA may also cause lower negative affect
454 (but not influence positive affect), (2) evidence of bidirectional effects (i.e., higher risk of
455 depression and lower wellbeing may also cause poorer GCA). Taken together, these MR
456 findings suggest a potential bidirectional causal relationship between mental health
457 and cognition.

458 Whilst our results could indicate a bidirectional causal effect, other explanations
459 (which violate MR assumptions) may account for these results including: (1) correlated
460 pleiotropy and (2) population-level confounding. Correlated pleiotropy occurs when
461 genetic variants used in MR analyses affect both the exposure and outcome via a
462 shared heritable factor (Morrison et al., 2020). An example of how this could occur here
463 is through genetic variants impacting brain-related processes (e.g., synaptic plasticity)
464 which directly affect both cognition and mental health. Whilst we did include several
465 MR methods which allow for some correlated pleiotropy (e.g., weighted median,
466 weighted mode, MR CAUSE) (Morrison et al., 2020), these methods could still give
467 biased estimates (and lead to incorrect conclusions regarding causality) if the *majority*
468 of instruments exhibit correlated pleiotropy. Another factor which may account for
469 these results is population-level confounding (e.g., assortative mating, dynastic effects)
470 (Brumpton et al., 2020). Whilst we are interested in direct effects from GWAS (i.e.,
471 genetic variants effect on phenotypic variation), for many phenotypes GWAS will also
472 pick up indirect effects (e.g., dynastic effects: parental genotype affecting offspring
473 phenotype via environmental factors). This is problematic as it violates MR assumptions
474 and could lead to incorrect conclusions (Brumpton et al., 2020). One approach
475 proposed to overcome this is to use within-family GWAS (Brumpton et al., 2020; Howe
476 et al., 2022). Howe et al. (2022) found that GWAS estimates for some phenotypes,
477 including cognitive ability and depressive symptoms, were attenuated when using
478 within-sibship GWAS compared to population-level GWAS (Howe et al., 2022). To try to
479 address this, we also conducted MR using within-sibship GWAS (depressive symptoms,
480 wellbeing, and cognitive ability) to test whether this impacted our findings.
481 Unfortunately, confidence intervals (CIs) were very large with imprecise estimates
482 (Supplementary Methods and Figure S16). This is unsurprising given the much smaller
483 sample size of within-sibship GWAS compared to population-level GWAS and highlights
484 the need for larger within-family GWAS on complex phenotypes like cognitive ability and
485 depressive symptoms.

486 4.2. *Additional Insights from Genetic Analyses on Negative and Positive Affect, and* 487 *Cognitive Performance.*

488 Genetic correlation analyses reveal key insights into the genetic architecture of
489 these phenotypes. First, as predicted, there was moderate genetic overlap between
490 negative affect and mental health phenotypes (depression $r_g=0.51$; anxiety $r_g=0.70$;
491 wellbeing $r_g = -0.71$), and between cognitive domains and cognition-related phenotypes
492 (GCA, brain volume; $r_g \leq 0.66$). This suggests that although these phenotypes are
493 related, they are not interchangeable but rather have partly distinct genetic
494 components. Second, as expected based on phenotypic correlations, genetic

495 correlation between negative and positive affect suggest they are dissociable
496 constructs as opposed to being opposite ends of the same spectrum ($r_g = -0.18$)
497 (Watson et al., 1988). Third, compared to positive affect, negative affect has higher
498 genetic overlap with GCA ($r_g = -0.19$ vs -0.06). This could indicate that negative affect has
499 a higher shared neural basis with GCA than positive affect and/or GCA and negative
500 affect may exhibit causal relationships (as suggested by our MR results).

501 Despite the negative affect GWAS having a much smaller sample size than the
502 depression GWAS (N=57,946 versus N=1,035,760), when used as an outcome, we
503 found more consistent evidence that GCA may play a causal role in negative affect
504 across MR methods. Speculatively, this may be because the GWAS on negative affect
505 consists of a more homogeneous phenotype which may increase statistical power and
506 impact effect estimates (Manchia et al., 2013). This highlights the importance of future
507 studies conducting GWAS on more homogeneous phenotypes (Nagel et al., 2018).
508 Whilst we focused on transdiagnostic features of positive and negative affect and
509 specific cognitive domains, there is a need for GWAS on other transdiagnostic features
510 [e.g., sleep disturbances, anhedonia, hot cognition (Roiser & Sahakian, 2013)]. It is
511 likely that advances will also be gained by parsing heterogeneity using other
512 approaches. For example, GWAS on depressed patients with specific characteristics
513 [e.g., immune-metabolic depression (Milaneschi et al., 2020)]. Research focusing on
514 improving the validity of subtypes within and across psychiatric conditions will be
515 necessary for advancing our understanding of these conditions (Hammen, 2018).

516 4.3. *Limitations*

517 Limitations of this study must be considered when interpreting the results. First,
518 smaller sample sizes for some GWAS resulted in a lack of genome-wide significant
519 variants ($p < 5 \times 10^{-8}$) and/or larger CIs in MR analyses (positive and negative affect,
520 specific cognitive domains, anxiety). Consortia combining data from several large
521 datasets are necessary to provide well-powered GWAS on these phenotypes; our GWAS
522 in the Lifelines Cohort will provide a useful contribution to this endeavour. Second, MR
523 estimates lifetime effect of an exposure (e.g., depression) on an outcome (e.g., GCA)
524 (Sanderson et al., 2022). Whilst this study is informative for understanding lifetime risk,
525 it is unclear what time periods would be best to intervene on. This requires either a
526 randomised controlled trial (RCT; which would be expensive and time consuming) or MR
527 with large GWAS on exposures and outcomes at specific ages in the lifespan (Power et
528 al., 2023). Third, cognitive performance is highly related to other socioeconomic
529 phenotypes (e.g., education, socioeconomic status). Future studies testing
530 independent effects and interactions between these phenotypes on mental health
531 using other methods (e.g., multivariable MR) would be useful (see Marchi et al., 2024).
532 Fourth, as discussed above, observed bidirectional causal relationships in MR analyses
533 between mental health and GCA could instead be due to violation of MR assumptions.
534 Triangulating results from standard MR analyses with other methods (e.g., within-
535 sibship MR) may help to increase confidence in conclusions drawn. Fifth, many GWAS
536 use data from large population-based cohorts which are less representative of some

537 populations (e.g., less affluent people) which may hinder generalizability of the findings.
538 Sixth, for continuous variables (e.g., GCA, negative affect, wellbeing), our study cannot
539 shed light on whether these relationships are nonlinear. As currently available nonlinear
540 MR approaches have provided implausible results (Wade et al., 2023), there is a need
541 for other methods to be used to characterise the shape of these relationships (see
542 Pines et al., 2024). Seventh, we focus on a subset of phenotypes, future studies should
543 expand this to provide insight into other mental health and cognitive phenotypes which
544 may show different relationships (e.g., schizophrenia, hot cognition) (Danahauer et al.,
545 2013). Finally, many GWAS on psychiatric conditions do not exclude people with
546 comorbidities. For example, the depression GWAS includes UK Biobank which defines
547 depression based on the following question: “Have you ever seen a general practitioner
548 (or psychiatrist) for nerves, anxiety, tension, or depression?”. This may result in many
549 individuals with anxiety being characterised as having depression and makes it
550 challenging to conduct subsequent analyses testing genetic overlap/causality between
551 different conditions.

552 4.4. *Implications*

553 Our GWAS on positive and negative affect and cognitive domains in the Lifelines
554 Cohort provide valuable resources which may facilitate insights into aetiology,
555 comorbidity, and causal risk factors for these phenotypes. We found evidence of
556 potential causal relationships between mental health phenotypes (negative affect,
557 depression, anxiety, wellbeing) and GCA. This may suggest that strategies targeting poor
558 mental health may prevent/treat cognitive dysfunction, and *vice versa*. However, to
559 increase confidence in this finding, triangulation using other methods which have
560 different strengths/limitations to MR, and consideration of highly related phenotypes
561 (e.g., education), are needed. Additionally, GWAS on other transdiagnostic phenotypes
562 are necessary to enable clearer insights into potential causal relationships. If multiple
563 lines of evidence support causality, careful consideration of potential interventions
564 (e.g., age to intervene, length of intervention, whether interventions targeting
565 depression to reduce poorer GCA [or *vice versa*] could also have their own direct effect
566 of GCA) would be necessary. This could have important implications for clinical
567 practice (e.g., targeting depression may help prevent/treat cognitive impairments in
568 health conditions such as dementia; cognitive remediation therapy may help
569 prevent/treat depression). Considering the broader literature (Demange et al., 2024;
570 Marchi et al., 2024), policy changes targeting factors impacting GCA [e.g., education
571 (Anderson et al., 2020)] would potentially be promising for reducing future mental
572 health challenges in the general population.

573 Nevertheless, there is also evidence suggesting that cognitive impairments can
574 persist in remitted depressed individuals (Semkovska et al., 2019). This may appear to
575 contrast the idea that treating depression may help to prevent/treat cognitive
576 impairments. Speculatively, this could be because: (1) once depressive symptoms have
577 decreased, cognitive impairments reduce but require a longer time to observe effects
578 (RCTs may not have long enough follow-up lengths), (2) reducing depression may help

579 to prevent cognitive impairments, but may not help treat them once they are already
580 experienced (i.e., a ‘scar effect’), (3) treating depression may improve cognition in a
581 subset of people (not all individuals), and/or (4) some symptoms of depression when
582 treated may improve cognition (but not all symptoms when treated will improve
583 cognition). There is a need for research testing these different theories to better
584 understand the dynamic relationship between depression and cognition.

585 4.5. *Conclusions*

586 In summary, we conducted GWAS on transdiagnostic features of many health
587 conditions (positive and negative affect, four specific cognitive domains). We identified
588 one genome-wide hit ($p < 5 \times 10^{-8}$) for reaction time, and many loci with suggestive
589 associations ($p < 5 \times 10^{-6}$) for other cognitive phenotypes. Follow-up gene mapping and
590 tissue expression analyses of suggestive hits show higher gene expression in brain
591 tissue compared to other tissues for most phenotypes. Genetic correlation analyses
592 show that negative and positive affect are dissociable constructs, with negative affect
593 having higher genetic overlap with GCA than positive affect. Importantly, in MR
594 analyses, we found evidence of a potential causal effect of higher GCA on multiple
595 mental health phenotypes (reduced negative affect, depression, and anxiety; and
596 increased wellbeing), with little evidence on positive affect. We also report evidence of
597 potential causal effects of depression and lower wellbeing on reduced GCA. Taken
598 together, as the most robust evidence was for GCA on negative affect, with little effect
599 on positive affect, this suggests that GCA may be a valid target for negative affect (but
600 not positive affect) and depression and wellbeing may be valid targets for GCA. Further
601 research testing the relationship between depression and cognition using
602 complementary research designs is warranted, particularly there is a need for studies to
603 test different theories we proposed in the discussion.

604

605 **Acknowledgements**

606 The generation and management of GWAS genotype data for the Lifelines Cohort Study
607 is supported by the UMCG Genetics Lifelines Initiative (UGLI). UGLI is partly supported
608 by a Spinoza Grant from NWO, awarded to Cisca Wijmenga. The authors wish to
609 acknowledge the services of the Lifelines Cohort Study, the contributing research
610 centers delivering data to Lifelines, and all the study participants.

611 The Genotype-Tissue Expression (GTEx) Project was supported by the [Common Fund](#) of
612 the Office of the Director of the National Institutes of Health, and by NCI, NHGRI,
613 NHLBI, NIDA, NIMH, and NINDS. The final data used for the analyses described in this
614 manuscript were obtained from: the GTEx Portal via FUMA on 01/07/2024 and
615 18/07/2024.

616 **Ethics approval**

617 The general Lifelines protocol has been approved by the UMCG Medical ethical
618 committee under number 2007/152.

619 **Funding**

620 The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of
621 Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University
622 Medical Center Groningen (UMCG), Groningen University and the Provinces in the North
623 of the Netherlands (Drenthe, Friesland, Groningen).

624 This work was supported by a UK Medical Research Council (MRC) grant to GMK
625 (MC_UU_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the
626 University of Bristol. The grant also supports CS. NMG acknowledges funding support by
627 Harvard University's Mind Brain Behavior Interfaculty Initiative and National Institute of
628 Mental Health grant K23MH132893. GMK acknowledges additional funding support
629 from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1;
630 MR/S037675/1; and MR/Z50354X/1), and the UK National Institute of Health and Care
631 Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). GH is supported
632 by the MRC (MC_UU_00032/01), and the NIHR Bristol Biomedical Research Centre
633 (NIHR 203315). The views expressed are those of the authors and not necessarily those
634 of the NIHR or the Department of Health and Social Care, UK.

635 **Contributions**

636 CS, GK, CH, NMG and GH conceptualized and designed the study. CS analyzed the data
637 and drafted the manuscript. All authors advised on the project/analysis and approved
638 the final version of the manuscript.

639 **Conflicts of Interest**

640 No conflicts of interest were reported.

641

642

643

References

- 644 Als, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T.,
645 Naamanka, J., Veerapen, K., Levey, D. F., Bendl, J., Bybjerg-Grauholm, J., Zeng, B.,
646 Demontis, D., Rosengren, A., Athanasiadis, G., Bækved-Hansen, M., Qvist, P.,
647 Bragi Walters, G., ... Børglum, A. D. (2023). Depression pathophysiology, risk
648 prediction of recurrence and comorbid psychiatric disorders using genome-wide
649 analyses. *Nature Medicine*, 29(7), 1832–1844.
- 650 Anderson, E. L., Howe, L. D., Wade, K. H., Ben-Shlomo, Y., Hill, W. D., Deary, I. J.,
651 Sanderson, E. C., Zheng, J., Korologou-Linden, R., Stergiakouli, E., Davey Smith, G.,
652 Davies, N. M., & Hemani, G. (2020). Education, intelligence and Alzheimer's
653 disease: evidence from a multivariable two-sample Mendelian randomization
654 study. *International Journal of Epidemiology*, 49(4), 1163–1172.
- 655 Ani, A., Van Der Most, P. J., Snieder, H., Vaez, A., & Nolte, I. M. (2021). GWASinspector:
656 comprehensive quality control of genome-wide association study results.
657 *Bioinformatics (Oxford, England)*, 37(1), 129–130.
- 658 Ball, E. L., Morillo, L., Poyner, E., McIntosh, A. M., & Iveson, M. H. (2024). Cognitive
659 ability in early life and risk of depression in adulthood: A systematic review and
660 meta-analysis. *Journal of Affective Disorders*, 352, 498–508.
- 661 Baselmans, B. M. L., Jansen, R., Ip, H. F., van Dongen, J., Abdellaoui, A., van de Weijer,
662 M. P., Bao, Y., Smart, M., Kumari, M., Willemsen, G., Hottenga, J. J., Boomsma, D.
663 I., de Geus, E. J. C., Nivard, M. G., & Bartels, M. (2019). Multivariate genome-wide
664 analyses of the well-being spectrum. *Nature Genetics*, 51(3), 445–451.
- 665 Brumpton, B., Sanderson, E., Heilbron, K., Hartwig, F. P., Harrison, S., Vie, G. Å., Cho,
666 Y., Howe, L. D., Hughes, A., Boomsma, D. I., Havdahl, A., Hopper, J., Neale, M.,
667 Nivard, M. G., Pedersen, N. L., Reynolds, C. A., Tucker-Drob, E. M., Grotzinger, A.,
668 Howe, L., ... Davies, N. M. (2020). Avoiding dynastic, assortative mating, and
669 population stratification biases in Mendelian randomization through within-family
670 analyses. *Nature Communications* 2020 11:1, 11(1), 1–13.
- 671 Bulik-Sullivan, B., Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P. R., Duncan,
672 L., Perry, J. R. B., Patterson, N., Robinson, E. B., Daly, M. J., Price, A. L., & Neale, B.
673 M. (2015). An atlas of genetic correlations across human diseases and traits.
674 *Nature Genetics* 2015 47:11, 47(11), 1236–1241.
- 675 Bulik-Sullivan, B., Loh, P. R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M.
676 J., Price, A. L., Neale, B. M., Corvin, A., Walters, J. T. R., Farh, K. H., Holmans, P. A.,
677 Lee, P., Collier, D. A., Huang, H., Pers, T. H., Agartz, I., Agerbo, E., ... O'Donovan, M.
678 C. (2015). LD Score regression distinguishes confounding from polygenicity in
679 genome-wide association studies. *Nature Genetics* 2015 47:3, 47(3), 291–295.
- 680 Carey, C., Strong, R., Huang, Y., Aslibekyan, S., Gentleman, R., Smoller, J., Wilmer, J.,
681 Robinson, E., & Germine, L. (2021). Shared and Distinct Genetic Influences
682 Between Cognitive Domains and Psychiatric Disorder Risk Based on Genome-
683 Wide Data. *Biological Psychiatry*, 89(9), S45–S46.

- 684 Chavez-Baldini, U., Nieman, D. H., Keestra, A., Lok, A., Mocking, R. J. T., De Koning, P.,
685 Krzhizhanovskaya, V. V., Bockting, C. L. H., Van Rooijen, G., Smit, D. J. A.,
686 Sutherland, A. L., Verweij, K. J. H., Van Wingen, G., Wigman, J. T. W., Vulink, N. C., &
687 Denys, D. (2023). The relationship between cognitive functioning and
688 psychopathology in patients with psychiatric disorders: a transdiagnostic network
689 analysis. *Psychological Medicine*, 53(2), 476.
- 690 Colwell, M. J., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., &
691 Murphy, S. E. (2022). Pharmacological targeting of cognitive impairment in
692 depression: recent developments and challenges in human clinical research.
693 *Translational Psychiatry* 2022 12:1, 12(1), 1–16.
- 694 Crawford, J. R., & Henry, J. D. (2004). The positive and negative affect schedule
695 (PANAS): construct validity, measurement properties and normative data in a large
696 non-clinical sample. *The British Journal of Clinical Psychology*, 43(Pt 3), 245–265.
- 697 Cuthbert, B. N. (2014). The RDoC framework: facilitating transition from ICD/DSM to
698 dimensional approaches that integrate neuroscience and psychopathology. *World*
699 *Psychiatry*, 13(1), 28–35.
- 700 Dam, V. H., Stenbæk, D. S., Köhler-Forsberg, K., Ip, C., Ozenne, B., Sahakian, B. J.,
701 Knudsen, G. M., Jørgensen, M. B., & Frokjaer, V. G. (2021). Hot and cold cognitive
702 disturbances in antidepressant-free patients with major depressive disorder: a
703 NeuroPharm study. *Psychological Medicine*, 51(14), 2347–2356.
- 704 Danhauer, S. C., Legault, C., Bandos, H., Kidwell, K., Costantino, J., Vaughan, L., Avis,
705 N. E., Rapp, S., Coker, L. H., Naughton, M., Naylor, C., Terracciano, A., &
706 Shumaker, S. (2013). Positive and negative affect, depression, and cognitive
707 processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR)
708 Trial. *Neuropsychology, Development, and Cognition. Section B, Aging,*
709 *Neuropsychology and Cognition*, 20(5), 532–552.
- 710 Davey Smith, G., & Ebrahim, S. (2003). “Mendelian randomization”: Can genetic
711 epidemiology contribute to understanding environmental determinants of
712 disease? *International Journal of Epidemiology*, 32(1), 1–22.
- 713 Demange, P. A., Boomsma, D. I., van Bergen, E., & Nivard, M. G. (2024). Educational
714 attainment and psychiatric diagnoses: a national registry data and two-sample
715 Mendelian randomization study. *Nature Mental Health* 2024 2:6, 2(6), 668–679.
- 716 Hammen, C. (2018). Risk Factors for Depression: An Autobiographical Review. *Annual*
717 *Review of Clinical Psychology*, 14(Volume 14, 2018), 1–28.
- 718 Hemani, G., Elsworth, B., Palmer, T., & Rasteiro, R. (2024). *ieugwasr: Interface to the*
719 *“OpenGWAS” Database API. R package version 1.0.1,*
720 *<https://mrcieu.github.io/ieugwasr/>. <https://github.com/MRCIEU/ieugwasr>*
- 721 Hemani, Gibran, Tilling, K., & Davey Smith, G. (2017). Orienting the causal relationship
722 between imprecisely measured traits using GWAS summary data. *PLOS Genetics*,
723 13(11), e1007081.
- 724 Hemani, Gibran, Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin,

- 725 C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A.,
726 Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T.
727 R., & Haycock, P. C. (2018). The MR-base platform supports systematic causal
728 inference across the human phenome. *ELife*, 7.
- 729 Hilton, R. A., Tozzi, L., Nesamoney, S., Kozłowska, K., Kohn, M. R., Harris, A., Clarke, S.,
730 & Williams, L. M. (2024). Transdiagnostic neurocognitive dysfunction in children
731 and adolescents with mental illness. *Nature Mental Health* 2024 2:3, 2(3), 299–
732 309.
- 733 Howe, L. J., Nivard, M. G., Morris, T. T., Hansen, A. F., Rasheed, H., Cho, Y., Chittoor, G.,
734 Ahlskog, R., Lind, P. A., Palviainen, T., van der Zee, M. D., Cheesman, R., Mangino,
735 M., Wang, Y., Li, S., Klaric, L., Ratliff, S. M., Bielak, L. F., Nygaard, M., ... Davies, N.
736 M. (2022). Within-sibship genome-wide association analyses decrease bias in
737 estimates of direct genetic effects. *Nature Genetics* 2022 54:5, 54(5), 581–592.
- 738 Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., &
739 Wang, P. (2010). Research Domain Criteria (RDoC): Toward a New Classification
740 Framework for Research on Mental Disorders. *American Journal of Psychiatry*,
741 167(7), 748–751.
- 742 Jansen, P. R., Nagel, M., Watanabe, K., Wei, Y., Savage, J. E., de Leeuw, C. A., van den
743 Heuvel, M. P., van der Sluis, S., & Posthuma, D. (2020). Genome-wide meta-
744 analysis of brain volume identifies genomic loci and genes shared with
745 intelligence. *Nature Communications* 2020 11:1, 11(1), 1–12.
- 746 Lam, M., Chen, C.-Y., Ge, T., Xia, Y., Hill, D. W., Trampush, J. W., Yu, J., Knowles, E.,
747 Davies, G., Stahl, E. A., Huckins, L., Liewald, D. C., Djurovic, S., Melle, I.,
748 Christoforou, A., Reinvang, I., DeRosse, P., Lundervold, A. J., Steen, V. M., ... Lencz,
749 T. (2021). Identifying nootropic drug targets via large-scale cognitive GWAS and
750 transcriptomics. *Neuropsychopharmacology*, 17, 47.
- 751 Mac Giollabhui, N. (2021). Inflammation and depression: Research designs to better
752 understand the mechanistic relationships between depression, inflammation,
753 cognitive dysfunction, and their shared risk factors. *Brain, Behavior, & Immunity -*
754 *Health*, 15.
- 755 Manchia, M., Cullis, J., Turecki, G., Rouleau, G. A., Uher, R., & Alda, M. (2013). The
756 impact of phenotypic and genetic heterogeneity on results of genome wide
757 association studies of complex diseases. *PloS One*, 8(10).
- 758 Marchi, M., Alkema, A., Xia, C., Thio, C. H. L., Chen, L. Y., Schalkwijk, W., Galeazzi, G.
759 M., Ferrari, S., Pingani, L., Kweon, H., Evans-Lacko, S., David Hill, W., & Boks, M. P.
760 (2024). Investigating the impact of poverty on mental illness in the UK Biobank
761 using Mendelian randomization. *Nature Human Behaviour* 2024, 1–13.
- 762 Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J. A., Ziyatdinov, A.,
763 Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., Habegger, L., Ferreira, M.,
764 Baras, A., Reid, J., Abecasis, G., Maxwell, E., & Marchini, J. (2021). Computationally
765 efficient whole-genome regression for quantitative and binary traits. *Nature*
766 *Genetics* 2021 53:7, 53(7), 1097–1103.

- 767 Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020). Depression
768 Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic
769 Depression. *Biological Psychiatry*, 88(5), 369–380.
- 770 Minikel, E. V., Painter, J. L., Dong, C. C., & Nelson, M. R. (2024). Refining the impact of
771 genetic evidence on clinical success. *Nature 2024* 629:8012, 629(8012), 624–629.
- 772 Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M., & He, X. (2020). Mendelian
773 randomization accounting for correlated and uncorrelated pleiotropic effects using
774 genome-wide summary statistics. *Nature Genetics 2020* 52:7, 52(7), 740–747.
- 775 Nagel, M., Watanabe, K., Stringer, S., Posthuma, D., & Van Der Sluis, S. (2018). Item-
776 level analyses reveal genetic heterogeneity in neuroticism. *Nature*
777 *Communications 2018* 9:1, 9(1), 1–10.
- 778 Otowa, T., Hek, K., Lee, M., Byrne, E. M., Mirza, S. S., Nivard, M. G., Bigdeli, T., Aggen, S.
779 H., Adkins, D., Wolen, A., Fanous, A., Keller, M. C., Castelao, E., Kutalik, Z., Der
780 Auwera, S. V., Homuth, G., Nauck, M., Teumer, A., Milaneschi, Y., ... Hettema, J. M.
781 (2016). Meta-analysis of genome-wide association studies of anxiety disorders.
782 *Molecular Psychiatry*, 21(10), 1391–1399.
- 783 Pines, A., Tozzi, L., Bertrand, C., Keller, A. S., Zhang, X., Whitfield-Gabrieli, S., Hastie, T.,
784 Larsen, B., Leikauf, J., & Williams, L. M. (2024). Psychiatric Symptoms, Cognition,
785 and Symptom Severity in Children. *JAMA Psychiatry*.
- 786 Power, G. M., Sanderson, E., Pagoni, P., Fraser, A., Morris, T., Prince, C., Frayling, T. M.,
787 Heron, J., Richardson, T. G., Richmond, R., Tyrrell, J., Warrington, N., Davey Smith,
788 G., Howe, L. D., & Tilling, K. M. (2023). Methodological approaches, challenges,
789 and opportunities in the application of Mendelian randomisation to lifecourse
790 epidemiology: A systematic literature review. *European Journal of Epidemiology*
791 2023 39:5, 39(5), 501–520.
- 792 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller,
793 J., Sklar, P., De Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). PLINK: A Tool Set
794 for Whole-Genome Association and Population-Based Linkage Analyses. *American*
795 *Journal of Human Genetics*, 81(3), 559.
- 796 Regier, D. A., Kuhl, E. A., & Kupfer, D. J. (2013). The DSM-5: Classification and criteria
797 changes. *World Psychiatry*, 12(2), 92–98.
- 798 Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014). Cognitive impairment in
799 depression: A systematic review and meta-analysis. *Psychological Medicine*,
800 44(10), 2029–2040.
- 801 Roiser, J. P., & Sahakian, B. J. (2013). Hot and cold cognition in depression. *CNS*
802 *Spectrums*, 18(3), 139–149.
- 803 Ross, T. P. (2014). The reliability and convergent and divergent validity of the Ruff Figural
804 Fluency Test in healthy young adults. *Archives of Clinical Neuropsychology : The*
805 *Official Journal of the National Academy of Neuropsychologists*, 29(8), 806–817.
- 806 Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden,
807 D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J.,

- 808 Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute
809 and longer-term outcomes in depressed outpatients requiring one or several
810 treatment steps: a STAR*D report. *The American Journal of Psychiatry*, *163*(11),
811 1905–1917.
- 812 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R.,
813 Palmer, T., Schooling, C. M., Wallace, C., Zhao, Q., & Davey Smith, G. (2022).
814 Mendelian randomization. *Nature Reviews Methods Primers*, *2*(1), 1–21.
- 815 Scholtens, S., Smidt, N., Swertz, M. A., Bakker, S. J. L., Dotinga, A., Vonk, J. M., Van Dijk,
816 F., Van Zon, S. K. R., Wijmenga, C., Wolffenbuttel, B. H. R., & Stolk, R. P. (2015).
817 Cohort Profile: LifeLines, a three-generation cohort study and biobank.
818 *International Journal of Epidemiology*, *44*(4), 1172–1180.
- 819 Semkowska, M., Quinlivan, L., O’Grady, T., Johnson, R., Collins, A., O’Connor, J., Knittle,
820 H., Ahern, E., & Gload, T. (2019). Cognitive function following a major depressive
821 episode: a systematic review and meta-analysis. *The Lancet Psychiatry*, *6*(10),
822 851–861.
- 823 Sijtsma, A., Rienks, J., Van Der Harst, P., Navis, G., Rosmalen, J. G. M., & Dotinga, A.
824 (2022). Cohort Profile Update: Lifelines, a three-generation cohort study and
825 biobank. *International Journal of Epidemiology*, *51*(5), E295–E302.
- 826 Suddell, S., Mahedy, L., Skirrow, C., Penton-Voak, I. S., Munafò, M. R., & Wootton, R. E.
827 (2023). Cognitive functioning in anxiety and depression: results from the ALSPAC
828 cohort. *Royal Society Open Science*, *10*(8).
- 829 Van De Weijer, M. P., Demange, P. A., Pelt, D. H. M., Bartels, M., & Nivard, M. G. (2024).
830 Disentangling potential causal effects of educational duration on well-being, and
831 mental and physical health outcomes. *Psychological Medicine*, *54*(7), 1403–1418.
- 832 Wade, K. H., Hamilton, F. W., Carslake, D., Sattar, N., Davey Smith, G., & Timpson, N. J.
833 (2023). Challenges in undertaking nonlinear Mendelian randomization. *Obesity*
834 (*Silver Spring, Md.*), *31*(12), 2887–2890.
- 835 Watanabe, K., Taskesen, E., Van Bochoven, A., & Posthuma, D. (2017). Functional
836 mapping and annotation of genetic associations with FUMA. *Nature*
837 *Communications* *2017* *8*:1, *8*(1), 1–11.
- 838 Watson, D, Clark, L. A., & Tellegen, A. (1988). Development and validation of brief
839 measures of positive and negative affect: the PANAS scales. *Journal of Personality*
840 *and Social Psychology*, *54*(6), 1063–1070.
- 841 Watson, David, Clark, L. A., & Tellegen, A. (1988). Development and validation of brief
842 measures of positive and negative affect: the PANAS scales. *Journal of Personality*
843 *and Social Psychology*, *54*(6), 1063–1070.
- 844 Wendt, F. R., Pathak, G. A., Tylee, D. S., Goswami, A., & Polimanti, R. (2020).
845 Heterogeneity and Polygenicity in Psychiatric Disorders: A Genome-Wide
846 Perspective. *Chronic Stress*, *4*.
- 847 Willer, C. J., Li, Y., & Abecasis, G. R. (2010). METAL: fast and efficient meta-analysis of
848 genomewide association scans. *Bioinformatics*, *26*(17), 2190.

849 Zainal, N. H., & Newman, M. G. (2021). Depression and worry symptoms predict future
850 executive functioning impairment via inflammation. *Psychological Medicine*.
851